文献速递皮肤肿瘤

原发黑色素瘤分期可预测晚期疾病生存:西班牙黑色素瘤登记研究GEM1801

Primary melanoma stage as a predictor of survival in advanced disease: Findings from the Spanish Melanoma Registry GEM1801.
PubMed 文献 · J Am Acad Dermatol · 2026-10-05

该研究基于西班牙黑色素瘤登记数据库(2018-2024),分析365例晚期黑色素瘤患者按原发分期的总生存。结论:I期黑色素瘤系统复发与更高肿瘤负荷和更差生存相关。

要点

  • I期黑色素瘤系统复发后中位总生存仅19.8个月,显著短于II/III期复发者
  • I期复发者更常见≥3个转移部位、脑转移和乳酸脱氢酶升高
  • I期黑色素瘤系统复发虽不常见,但占转移性黑色素瘤近三分之一

核心结论

  • I期黑色素瘤系统复发与更高肿瘤负荷和更差生存相关,生存劣于II/III期复发。

研究设计与样本

  • 基于西班牙黑色素瘤登记(2018-2024)的回顾性分析,纳入365例一线治疗的转移性黑色素瘤患者,按原发分期分层。

主要发现

  • 365例中,58例既往I期、32例IIA期、80例IIB/C期、195例III期。
  • 系统复发时,既往I期更常见≥3个转移部位(OR=1.89,95%CI 1.06-3.35)、脑转移(OR=4.02,95%CI 2.13-7.58)和乳酸脱氢酶升高(OR=2.19,95%CI 1.18-4.04)。

临床怎么用

  • 对I期黑色素瘤康复者应保持随访警觉,系统复发时需评估更高肿瘤负荷和脑转移风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic relapse after stage I melanoma is uncommon, but accounts for nearly one-third of metastatic melanoma cases. The prognostic impact of primary melanoma stage in advanced disease is unknown. METHODS: Overall survival was analyzed in patients with advanced melanoma from the Spanish Melanoma Registry (2018-2024), stratified by primary stage. RESULTS: Among 365 patients with metastatic melanoma treated at first line, 58 had prior stage I, 32 IIA, 80 IIB/C, and 195 III. Median time to relapse was 52 months for stage I, 30 months in IIA, 27 months in IIB/C and 25 months in stage III (P = .0001). At systemic relapse, patients with previous stage I more frequently had ≥3 metastatic sites (odds ratio [OR], 1.89; 95% confidence interval [CI], 1.06-3.35), brain metastases (OR, 4.02; 95% CI, 2.13-7.58), and elevated lactate dehydrogenase (OR 2.19, 95% CI, 1.18-4.04). Median overall survival was shorter for patients with prior stage I (19.8 m, 95% CI, 12-55.9) versus stage IIA (60.1 m, 95% CI, 52.8-not reached), IIB/C (32.6 m, 95% CI, 18.9-not reached), and III (43 m, 95% CI, 25.5-62.3) (P = .024). CONCLUSIONS: Systemic relapse after stage I melanoma is associated with higher tumor burden and poorer survival than relapse after stage II/III.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Cao M, Puig S, Manzano JL, et al. Primary melanoma stage as a predictor of survival in advanced disease: Findings from the Spanish Melanoma Registry GEM1801. J Am Acad Dermatol. 2026. PMID: 42833484. doi:10.1016/j.jaad.2026.09.112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。